Compare Amylx Pharmaceuticals Inc (AMLX) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Duke Energy Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Duke Energy Corp trades at $123.46 (market cap $96.05B). The key difference: Duke Energy Corp is far larger — about 36.4× Amylx Pharmaceuticals Inc's market cap, and Duke Energy Corp pays a 3.52% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DUK | |
|---|---|---|
Market Cap | $2.64B | $96.05B |
Sector | Health | Utilities |
52-Week High | $24.19 | $133.46 |
52-Week Low | $7.82 | $113.99 |
Enterprise Value | $2.39B | $188.56B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Duke Energy (DUK) trades at $121.19, down 2.93% on the day, with a bearish technical signal. The company reported strong Q2 2026 earnings of $1.43 per share, beating estimates, and maintains solid fundamentals with a 15.78% net income margin. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives like a $35 million equity units offering and data center growth opportunities.
The outlook is mixed; fundamentals are robust with consistent earnings beats and a healthy dividend, but technical weakness and high debt levels pose risks. Analyst consensus is a 'Hold' with a $136.17 price target, suggesting cautious optimism for long-term investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
